Hydrofluoric Acid and Other Impurities in Toxic Perfluorooctane Batches.

H-value cytotoxicity hydrofluoric acid perfluorocarbon liquids perfluorooctane retinal toxicity toxic impurities underfluorinated compounds

Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
May 2019
Historique:
received: 22 10 2018
accepted: 11 03 2019
entrez: 8 6 2019
pubmed: 7 6 2019
medline: 7 6 2019
Statut: epublish

Résumé

The complications with cytotoxic perfluorooctane (PFO) batches reported in 2015 were attributed to reactive underfluorinated impurities whose chemical identity and behavior still need to be clarified. We analyzed original packaged samples of Ala (A) The detected impurities can be divided into: (1) reactive underfluorinated compounds and their degradation products including hydrogen fluoride (HF), (2) nonreactive underfluorinated compounds, (3) surface active compounds, (4) nonreactive fluorinated compounds, and (5) leachables from primary packaging components. The highest acute toxic potential is associated with the impurities of group (1). (B) HF was detected as a degradation product of reactive underfluorinated impurities by relying on the pH values and fluoride ion content of the water extracts. (C) Lipophilic impurities dissolved in PFO migrate into lipophilic extraction medium. In particular, HF is rapidly transferred in this way. HF as degradation product of unstable or reactive underfluorinated contaminants seems of particular importance triggering the acute toxicity of affected PFO. Contamination related toxicity and unwanted side effects can only be reliably excluded via analytical controlled multistage, high-purification processes. In Ala

Identifiants

pubmed: 31171991
doi: 10.1167/tvst.8.3.24
pii: TVST-18-1192
pmc: PMC6543921
doi:

Types de publication

Journal Article

Langues

eng

Pagination

24

Références

Eur J Ophthalmol. 2000 Jul-Sep;10(3):189-97
pubmed: 11071025
Graefes Arch Clin Exp Ophthalmol. 2001 Jun;239(5):373-81
pubmed: 11482342
Graefes Arch Clin Exp Ophthalmol. 2001 Sep;239(9):635-42
pubmed: 11688661
Retina. 2004 Feb;24(1):110-5
pubmed: 15076951
Retina. 2005 Oct-Nov;25(7):902-10
pubmed: 16205571
Graefes Arch Clin Exp Ophthalmol. 2007 Jun;245(6):863-8
pubmed: 17120010
Am J Ophthalmol. 2007 Apr;143(4):707-9
pubmed: 17386289
Retina. 1991;11(4):367-74
pubmed: 1813951
J Toxicol Environ Health A. 2012;75(1):50-62
pubmed: 22047163
Invest Ophthalmol Vis Sci. 1990 Apr;31(4):638-46
pubmed: 2335433
Acta Ophthalmol. 2015 Aug;93(5):e400-2
pubmed: 25619682
Retina. 2017 Jun;37(6):1140-1151
pubmed: 28538613
Retina. 2018 Sep;38(9):1856-1864
pubmed: 28723847
Ophthalmologica. 2018;240(4):236-243
pubmed: 30001544
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):4841-4846
pubmed: 30347078
Biomater Artif Cells Immobilization Biotechnol. 1993;21(5):583-95
pubmed: 8117848

Auteurs

Dirk-Henning Menz (DH)

Pharmpur GmbH, Koenigsbrunn, Germany.

Nicolas Feltgen (N)

Department of Ophthalmology, University Medical Center, Goettingen, Germany.

Thorsten Lechner (T)

Pharmpur GmbH, Koenigsbrunn, Germany.

Helge Menz (H)

Pharmpur GmbH, Koenigsbrunn, Germany.

Bernd-Kristof Müller (BK)

Pharmpur GmbH, Koenigsbrunn, Germany.

Joachim Dresp (J)

Feldbergstr. 58a, Muenchen, Germany.

Hans Hoerauf (H)

Department of Ophthalmology, University Medical Center, Goettingen, Germany.

Classifications MeSH